Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Common Stock Shares Outstanding of 43.22 million shares for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +38.9% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: 32.89 million shares | Q3 2018: 33.10 million shares | Q1 2019: 33.58 million shares | Q2 2019: 38.71 million shares | Q3 2019: 38.94 million shares | Q1 2020: 39.45 million shares | Q2 2020: 48.24 million shares | Q3 2020: 48.29 million shares | Q1 2021: 48.60 million shares | Q2 2021: 58.51 million shares | Q3 2021: 58.78 million shares | Q1 2022: 58.80 million shares | Q2 2022: 58.80 million shares | Q3 2022: 60.56 million shares | Q1 2023: 60.65 million shares | Q2 2023: 60.65 million shares | Q3 2023: 14.82 million shares | Q1 2024: 29.35 million shares | Q2 2024: 29.35 million shares | Q3 2024: 29.37 million shares | Q1 2025: 32.13 million shares | Q2 2025: 32.18 million shares | Q3 2025: 42.85 million shares.
- Over the full 9 years of available data (2017 to 2025), Dianthus Therapeutics, Inc. /DE/'s Common Stock Shares Outstanding has grown by 1,738.3%.
- Historical annual values: Fiscal year 2025: 43.22 million shares | Fiscal year 2024: 31.12 million shares | Fiscal year 2023: 14.82 million shares | Fiscal year 2022: 875,279 shares | Fiscal year 2021: 58.80 million shares | Fiscal year 2020: 48.53 million shares | Fiscal year 2019: 39.26 million shares | Fiscal year 2018: 33.31 million shares | Fiscal year 2017: 2.35 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: